Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.
Hidehito Horinouchi, MD, PhD
Advertisement
Articles by Hidehito Horinouchi, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5